![glp 1 gip dual agonist mechanism of action GLP-1 & Agonists | Obesity and Diabetes Management | Harrison's updates (22nd Ed.) PDF] Novel dual GLP-1/GIP receptor](https://i.ytimg.com/vi/fWdhhzhvPkI/sddefault.jpg)
glp 1 gip dual agonist mechanism of action GLP-1 & Agonists | Obesity and Diabetes Management | Harrison's updates (22nd Ed.) PDF] Novel dual GLP-1/GIP receptor
Description
Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: A meta-analysis of randomized clinical trials
![glp 1 gip dual agonist mechanism of action GLP-1 & Agonists | Obesity and Diabetes Management | Harrison's updates (22nd Ed.) PDF] Novel dual GLP-1/GIP receptor](https://figures.semanticscholar.org/d83a64f6b7193358c31030487761fc19c80dd33c/3-Figure1-1.png)
This indicates that when evaluating the efficacy of different GLP-1RA drugs, varying treatment durations should be employed to fully reflect the therapeutic potential of each drug
![glp 1 gip dual agonist mechanism of action GLP-1 & Agonists | Obesity and Diabetes Management | Harrison's updates (22nd Ed.) PDF] Novel dual GLP-1/GIP receptor](https://www.mdpi.com/jcm/jcm-14-03812/article_deploy/html/images/jcm-14-03812-g001-550.jpg)
Oxyntomodulin inhibits food intake in the rat
![glp 1 gip dual agonist mechanism of action GLP-1 & Agonists | Obesity and Diabetes Management | Harrison's updates (22nd Ed.) PDF] Novel dual GLP-1/GIP receptor](https://lookaside.fbsbx.com/lookaside/crawler/media/?media_id=969476935847345)
As mentioned above, 70% of diabetes patients discontinue GLP-1 treatment within two years
![glp 1 gip dual agonist mechanism of action GLP-1 & Agonists | Obesity and Diabetes Management | Harrison's updates (22nd Ed.) PDF] Novel dual GLP-1/GIP receptor](https://www.researchgate.net/publication/370926483/figure/fig1/AS:11431281185395916@1693619319132/Schematic-illustration-of-monoagonists-dual-agonists-and-triple-agonists-based-on-GLP-1.png)
